Scynexis (SCYX) Short term Debt (2013 - 2023)

Scynexis' (SCYX) quarterly Short term Debt came in at $34.6 million in Q1 2023, up 371.47% on a QoQ basis from $7.3 million in Q3 2018.

Scynexis (SCYX) Short term Debt (2013 - 2023) Analysis & Trends

Scynexis (SCYX) has 5 years of Short term Debt data on file, last reported at $34.6 million in Q1 2023.

Quarterly Short term Debt changed N/A year-over-year to $34.6 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $34.6 million (changed N/A YoY) and the FY2017 annual result came in at $4.3 million, changed N/A from the prior year.
Short term Debt grew to $34.6 million in Q1 2023, from $7.3 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $34.6 million in Q1 2023 to a low of $34.6 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Scynexis	61.37 Mn	-53.33 Mn	-

Download Data